SCHEMBL1309058

SCHEMBL1309058

CCOC(=O)C1(C2CCCCC2)CCN(C(=O)[C@H](N)Cc2ccc(Cl)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MC4R P32245 8/20 0.56
MC3R P41968 8/20 0.56
MC1R Q01726 8/20 0.56
MC5R P33032 7/20 0.49
POLB P06746 1/20 0.46
CYP3A4 P08684 1/20 0.45
DPP7 Q9UHL4 6/20 0.45
DPP4 P27487 2/20 0.45
DPP8 Q6V1X1 2/20 0.45
FAP Q12884 1/20 0.45
DPP9 Q86TI2 1/20 0.45
AKT1 P31749 2/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1309061 1.00 MC4R (0.56) MC4RMC3RMC1RMC5RPOLB
SCHEMBL1308291 0.90 MC4R (0.46) MC4RMC3RMC1RMC5RPOLB
SCHEMBL1308288 0.90 MC4R (0.46) MC4RMC3RMC1RMC5RPOLB
Hydrochloric Acid SCHEMBL7557239 0.90 MC4R (0.46) MC4RMC3RMC1RMC5RPOLB
SCHEMBL1309125 0.90 DPP4 (0.49) MC4RMC3RMC1RMC5RDPP7
SCHEMBL1309122 0.90 DPP4 (0.49) MC4RMC3RMC1RMC5RDPP7
SCHEMBL6180759 0.86 MC4R (0.62) MC4RMC3RMC1RMC5RCYP3A4
Trifluoroacetic Acid SCHEMBL1309459 0.85 DPP4 (0.45) MC4RMC3RMC1RMC5RDPP7
SCHEMBL1309434 0.82 MC4R (0.59) MC4RMC3RMC1RMC5RCYP3A4
SCHEMBL1309435 0.82 MC4R (0.59) MC4RMC3RMC1RMC5RCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877968-B2 Melanocortin receptor modulators, process for preparing them and use there in human medicine and cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-11-04 US disclosed
EP-2352728-B1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS GALDERMA RES & DEV (FR) 2014-05-21 EP disclosed
US-20110275657-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-11-10 US disclosed
EP-2352728-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS Galderma Research & Development (FR) 2011-08-10 EP disclosed
WO-2010052255-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275657-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS MC1R, MC5R, MC3R MC4R 4/4885MC3R 3/4885MC1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.